Pembro-话题@MedSci

#Pembro#

98篇内容 | 2701人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1786968, encodeId=679c1e86968d2, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Blood : pembrolizumab治疗B细胞淋巴瘤的安全性和耐受性, objectType=article, longId=106516, objectId=1980106516d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1980106516d2, replyNumber=0, likeNumber=71, createdTime=2018-07-04, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1980106516d2, moduleTitle=Blood : pembrolizumab治疗B细胞淋巴瘤的安全性和耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1980106516d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786963, encodeId=835b1e869638e, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=The Lancet Oncology：Pembrolizumab用于晚期头颈癌, objectType=article, longId=94332, objectId=a4609433272, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4609433272, replyNumber=0, likeNumber=86, createdTime=2017-04-17, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4609433272, moduleTitle=The Lancet Oncology：Pembrolizumab用于晚期头颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4609433272)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786958, encodeId=16c11e8695801, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=JCO：Pembrolizumab治疗黑色素瘤患者中PD-L1表达量与缓解时间呈正相关（KEYNOTE-001）, objectType=article, longId=81794, objectId=916481e9401, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=916481e9401, replyNumber=0, likeNumber=98, createdTime=2017-10-18, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=916481e9401, moduleTitle=JCO：Pembrolizumab治疗黑色素瘤患者中PD-L1表达量与缓解时间呈正相关（KEYNOTE-001）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=916481e9401)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786967, encodeId=024e1e8696714, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=J CLIN ONCOL: Pembrolizumab治疗晚期程序性死亡因子配体 1-阳性的子宫内膜癌的安全及抗肿瘤活性（KEYNOTE-028）, objectType=article, longId=102865, objectId=a98d102865b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a98d102865b0, replyNumber=0, likeNumber=77, createdTime=2017-11-13, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a98d102865b0, moduleTitle=J CLIN ONCOL: Pembrolizumab治疗晚期程序性死亡因子配体 1-阳性的子宫内膜癌的安全及抗肿瘤活性（KEYNOTE-028）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a98d102865b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786966, encodeId=db541e86966ee, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Lancet Oncol：Pembrolizumab获批一线联合化疗治疗晚期NSCLC（KEYNOTE-021）, objectType=article, longId=99235, objectId=8d3699235ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d3699235ae, replyNumber=0, likeNumber=84, createdTime=2017-09-07, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d3699235ae, moduleTitle=Lancet Oncol：Pembrolizumab获批一线联合化疗治疗晚期NSCLC（KEYNOTE-021）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d3699235ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786964, encodeId=61281e86964c8, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Blood：PD-1抗体pembrolizumab治疗慢性淋巴细胞白血病Richter’s转化有效, objectType=article, longId=96976, objectId=a9ad969e617, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9ad969e617, replyNumber=0, likeNumber=87, createdTime=2017-08-28, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9ad969e617, moduleTitle=Blood：PD-1抗体pembrolizumab治疗慢性淋巴细胞白血病Richter’s转化有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9ad969e617)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786957, encodeId=5ff01e86957e5, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=FDA批准pembrolizumab作为高表达PD-L1转移性NSCLC的一线治疗, objectType=article, longId=81159, objectId=fe928115907, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe928115907, replyNumber=0, likeNumber=83, createdTime=2017-08-03, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe928115907, moduleTitle=FDA批准pembrolizumab作为高表达PD-L1转移性NSCLC的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe928115907)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786965, encodeId=92531e869650e, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=J Clin Oncol：pembrolizumab治疗复发难治的经典型霍奇金淋巴瘤有疗效, objectType=article, longId=97612, objectId=13239e612a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13239e612a5, replyNumber=0, likeNumber=74, createdTime=2017-09-16, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13239e612a5, moduleTitle=J Clin Oncol：pembrolizumab治疗复发难治的经典型霍奇金淋巴瘤有疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13239e612a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786955, encodeId=f1bb1e869551c, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=ASCO 2016：pembrolizumab和ipilimumab联合治疗晚期黑色素瘤的安全性和有效性在可接受范围(KEYNOTE-029), objectType=article, longId=71408, objectId=4379e1408e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4379e1408e0, replyNumber=0, likeNumber=74, createdTime=2016-07-11, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4379e1408e0, moduleTitle=ASCO 2016：pembrolizumab和ipilimumab联合治疗晚期黑色素瘤的安全性和有效性在可接受范围(KEYNOTE-029), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4379e1408e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786959, encodeId=0a6a1e8695945, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Lancet Oncol：Pembrolizumab配合化疗一线对晚期非鳞NSCLC有明显获益(KEYNOTE-021), objectType=article, longId=81880, objectId=e29e81880a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e29e81880a0, replyNumber=0, likeNumber=86, createdTime=2017-06-14, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e29e81880a0, moduleTitle=Lancet Oncol：Pembrolizumab配合化疗一线对晚期非鳞NSCLC有明显获益(KEYNOTE-021), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e29e81880a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786953, encodeId=46d41e8695374, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=NEJM：Pembrolizuma（抗PD-1）治疗晚期默克尔细胞癌的研究, objectType=article, longId=66809, objectId=2c0166809c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c0166809c0, replyNumber=0, likeNumber=80, createdTime=2016-06-12, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c0166809c0, moduleTitle=NEJM：Pembrolizuma（抗PD-1）治疗晚期默克尔细胞癌的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c0166809c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786956, encodeId=6e661e8695640, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=NEJM：Pembrolizumab治疗PD-L1阳性非小细胞肺癌，疗效十分显著, objectType=article, longId=79695, objectId=2555e969519, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2555e969519, replyNumber=0, likeNumber=120, createdTime=2017-08-25, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2555e969519, moduleTitle=NEJM：Pembrolizumab治疗PD-L1阳性非小细胞肺癌，疗效十分显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2555e969519)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786954, encodeId=f53b1e869547e, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=JAMA：Pembrolizumab 可有效治疗晚期黑色素瘤, objectType=article, longId=66899, objectId=cef066899cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cef066899cb, replyNumber=0, likeNumber=65, createdTime=2016-06-04, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cef066899cb, moduleTitle=JAMA：Pembrolizumab 可有效治疗晚期黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cef066899cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786952, encodeId=09561e8695230, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Lancet：Pembrolizumab能够显著延长PD-L1阳性晚期非小细胞肺癌患者的生存期, objectType=article, longId=60882, objectId=3e5560882c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e5560882c0, replyNumber=0, likeNumber=65, createdTime=2016-10-16, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e5560882c0, moduleTitle=Lancet：Pembrolizumab能够显著延长PD-L1阳性晚期非小细胞肺癌患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e5560882c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786951, encodeId=5df01e8695193, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=NEJM：Pembrolizumab用于晚期NSCLC展现出良好抗肿瘤活性（KEYNOTE-001研究）, objectType=article, longId=49813, objectId=9a844981343, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a844981343, replyNumber=0, likeNumber=94, createdTime=2015-12-20, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a844981343, moduleTitle=NEJM：Pembrolizumab用于晚期NSCLC展现出良好抗肿瘤活性（KEYNOTE-001研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a844981343)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786948, encodeId=bb011e869480a, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=SABCS 2014：Pembrolizumab使部分三阴性乳腺癌患者产生持续应答, objectType=article, longId=44049, objectId=e5794404941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5794404941, replyNumber=0, likeNumber=71, createdTime=2015-02-14, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5794404941, moduleTitle=SABCS 2014：Pembrolizumab使部分三阴性乳腺癌患者产生持续应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5794404941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786950, encodeId=75b11e86950fb, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=NEJM：晚期黑色素瘤治疗效果，Pembrolizumab V.S Ipilimumab, objectType=article, longId=49604, objectId=874149604c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=874149604c0, replyNumber=0, likeNumber=82, createdTime=2015-04-27, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=874149604c0, moduleTitle=NEJM：晚期黑色素瘤治疗效果，Pembrolizumab V.S Ipilimumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=874149604c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786949, encodeId=4e181e86949f8, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=PD-L1类药物Pembrolizumab用于胃癌安全有效(KEYNOTE-012研究), objectType=article, longId=45645, objectId=3d624564589, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d624564589, replyNumber=0, likeNumber=96, createdTime=2015-03-24, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d624564589, moduleTitle=PD-L1类药物Pembrolizumab用于胃癌安全有效(KEYNOTE-012研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d624564589)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Pembro

2020-05-29

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Blood : pembrolizumab治疗B细胞淋巴瘤的安全性和耐受性

2018-07-04

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

The Lancet Oncology：Pembrolizumab用于晚期头颈癌

2017-04-17

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

JCO：Pembrolizumab治疗黑色素瘤患者中PD-L1表达量与缓解时间呈正相关（KEYNOTE-001）

2017-10-18

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

J CLIN ONCOL: Pembrolizumab治疗晚期程序性死亡因子配体 1-阳性的子宫内膜癌的安全及抗肿瘤活性（KEYNOTE-028）

2017-11-13

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Lancet Oncol：Pembrolizumab获批一线联合化疗治疗晚期NSCLC（KEYNOTE-021）

2017-09-07

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Blood：PD-1抗体pembrolizumab治疗慢性淋巴细胞白血病Richter’s转化有效

2017-08-28

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

FDA批准pembrolizumab作为高表达PD-L1转移性NSCLC的一线治疗

2017-08-03

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

J Clin Oncol：pembrolizumab治疗复发难治的经典型霍奇金淋巴瘤有疗效

2017-09-16

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

ASCO 2016：pembrolizumab和ipilimumab联合治疗晚期黑色素瘤的安全性和有效性在可接受范围(KEYNOTE-029)

2016-07-11

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Lancet Oncol：Pembrolizumab配合化疗一线对晚期非鳞NSCLC有明显获益(KEYNOTE-021)

2017-06-14

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

NEJM：Pembrolizuma（抗PD-1）治疗晚期默克尔细胞癌的研究

2016-06-12

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

NEJM：Pembrolizumab治疗PD-L1阳性非小细胞肺癌，疗效十分显著

2017-08-25

仁医06 (审核中...)

前往app查看评论内容

#Pembro#

JAMA：Pembrolizumab 可有效治疗晚期黑色素瘤

2016-06-04

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Lancet：Pembrolizumab能够显著延长PD-L1阳性晚期非小细胞肺癌患者的生存期

2016-10-16

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

NEJM：Pembrolizumab用于晚期NSCLC展现出良好抗肿瘤活性（KEYNOTE-001研究）

2015-12-20

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

SABCS 2014：Pembrolizumab使部分三阴性乳腺癌患者产生持续应答

2015-02-14

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

NEJM：晚期黑色素瘤治疗效果，Pembrolizumab V.S Ipilimumab

2015-04-27

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

PD-L1类药物Pembrolizumab用于胃癌安全有效(KEYNOTE-012研究)

2015-03-24

科室
- - 订阅+
  - 更多科室
工具
服务